HCA Healthcare, Inc. HCA

HCA Healthcare Inc. filed its 10-Q for the quarter ended March 31, 2026, and the numbers are a study in contrasts. Revenue hit $19.11 billion, up from the same period last year, while net income came in at $1.62 billion. But the balance sheet is where things get interesting: shareholder equity is a startling negative $6.30 billion, cash and cash equivalents stand at $940 million, and operating cash flow is $2.01 billion. The company’s sprawling network includes 189 hospitals, 119 freestanding surgery centres, and 30 endoscopy centres, but its property sales during the quarter were so small they’re practically symbolic-$3 million in proceeds with a $1 million pre-tax loss. The filing reads like a hospital running on fumes, with a balance sheet that’s more intensive care than robust. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm)

HCA’s business is the unglamorous but essential work of running hospitals and outpatient facilities. The company’s scale is undeniable: 189 hospitals, 119 surgery centres, and 30 endoscopy centres, plus outpatient and ancillary services. But the quarterly filing reveals a company that’s haemorrhaging equity while generating healthy revenue. The $1.62 billion net income sounds impressive, but it’s set against a backdrop of negative equity and a cash conversion cycle that’s tighter than a hospital gown in a wind tunnel. The filing even includes a line item for inventory-$1.68 billion-which is more than the company’s entire cash pile. If HCA were a patient, it would be in the red zone. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm)

The 10-Q drops a few more breadcrumbs: earnings per share (diluted) clock in at $7.15, and the weighted average number of shares outstanding is 226.7 million. The company’s capital expenditures for the quarter were $1.12 billion, which is more than it spent on anything else except its day-to-day operations. Meanwhile, the net cash provided by operating activities was $2.01 billion, leaving a net free cash flow of roughly $890 million-barely enough to cover the company’s inventory. The filing also notes $1.68 billion in inventory, which is the kind of detail that makes you wonder if HCA is sitting on a mountain of bandages or a warehouse full of unpaid bills. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm)

For context, the company’s 8-K filed on June 18, 2026, doesn’t change the arithmetic, but it does confirm that HCA is still in the business of selling assets-albeit on a scale so small it’s barely worth mentioning. The 10-Q and 8-K together paint a picture of a company with strong revenue but a balance sheet that’s as stretched as a surgical glove in a pandemic. The operating cash flow is healthy, but the capital expenditures are relentless, and the equity is negative. It’s the kind of financial profile that would make a hospital administrator lose sleep, assuming they weren’t already losing it to staffing shortages and supply chain headaches. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm; SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/860730/000119312526275086/d163825d8k.htm)

The company’s inventory sits at $1.68 billion, which is more than its entire cash pile, and the capital expenditures are eating into operating cash flow like a hungry intern in the cafeteria. The filing doesn’t break down what’s in the inventory, but given HCA’s line of work, it’s safe to assume it’s not just surgical gloves and bandages-it’s also unpaid bills, outstanding receivables, and the kind of administrative detritus that accumulates when you’re running 189 hospitals. The company’s ability to convert revenue into cash is the real story here, and the numbers suggest it’s a work in progress. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm)

The filing doesn’t provide guidance, and there’s no mention of dividends or buybacks, which is notable for a company that’s generating $1.62 billion in net income but sitting on negative equity. The lack of shareholder-friendly actions suggests management is more focused on survival than celebration. The company’s 8-K and 10-Q together suggest a business that’s doing the hard yards of healthcare delivery but struggling to convert its revenue into balance sheet strength. The tension is real, and the numbers don’t lie-unless you’re the kind of accountant who rounds to the nearest billion. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/860730/000119312526191444/hca-20260331.htm; SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/860730/000119312526275086/d163825d8k.htm)